Emerging Opportunities in Neglected Tropical Disease Market by 2034
New York, Tuesday, 1 July 2025.
The market for neglected tropical disease treatments is projected to grow significantly, driven by new health surveillance technologies and climate change impacts. This presents unique investment opportunities.
Market Growth and Key Drivers
The neglected tropical disease (NTD) treatment market is set to grow from $3.36 billion in 2024 to $3.57 billion in 2025, with a compound annual growth rate (CAGR) of 6.3% over the period [1]. This expansion is expected to continue, reaching $4.52 billion by 2029, driven by factors such as the enhancement of disease surveillance technologies, the introduction of new treatments and vaccines, efforts to tackle antimicrobial resistance, and improved cross-border collaborations [1]. Moreover, the impact of climate change, which influences the spread of tropical diseases, further underscores the necessity for efficient treatment strategies and presents significant investment opportunities.
Geographical Focus and Opportunities
The Asia-Pacific region occupied the largest share of the NTD treatment market in 2024, pointing to substantial investment potentials in this area [1]. Countries from this region, such as Thailand, witness a collaborative push towards developing accessible treatments, underscored by partnerships like the one between Thailand’s Government Pharmaceutical Organization, DNDi, and Pharco Pharmaceuticals aimed at registering effective hepatitis C treatments [2]. Initiatives like these not only address regional health challenges but also offer lucrative avenues for investors eyeing long-term engagement in the healthcare sector.
Investment Landscape and Key Players
Prominent pharmaceutical companies such as Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., and AstraZeneca PLC are already investing heavily in this market [1]. In a notable move, Novartis AG invested $250 million in 2022 towards combating NTDs and malaria, showcasing the high stakes and investment inflow in these medical challenges [1]. This financial commitment signals confidence in the market’s future and underscores an attractive investment landscape for both established pharmaceutical giants and new investors.
Future Prospects by 2034
The Business Research Company’s report projects continued growth for the NTD treatment market, forecasting a CAGR of 6.2% from 2025 to 2030 [1]. This trend suggests that by 2034, the market will have expanded significantly, offering compelling opportunities for stakeholders aiming to address global healthcare inequities while benefiting financially. This growth aligns with strategic health goals set by international bodies like the WHO, emphasizing disease prevention, treatment integration, and health system strengthening [3].